Skip to main content

Warning notification:Warning

Unfortunately, you are using an outdated browser. Please, upgrade your browser to improve your experience with HSE. The list of supported browsers:

  1. Chrome
  2. Edge
  3. FireFox
  4. Opera
  5. Safari
HSE National Clinical Guideline

HSE National Clinical Guideline for Safe Diabetes Management following Levemir® (Insulin Detemir) Discontinuation


Topic: Safe diabetes management following levemir® (insulin detemir) discontinuation
Document Owner: National Clinical Programme for Diabetes and National Clinical Programme for Paediatric Diabetes
National Group: National Clinical Programme for Diabetes and National Clinical Programme for Paediatric Diabetes
Effective From: 19 March 2026
The HSE has developed this clinical guideline to support health care professionals in selecting and safely initiating alternative basal insulins in advance of the Levemir® (insulin detemir) discontinuation.
HSE National Clinical Guideline for Safe Diabetes Management following Levemir® (Insulin Detemir) Discontinuation
PDF, 0.69MB

This document was developed in response to the Novo Nordisk discontinuation of Levemir® (insulin detemir) in both Penfill® and Flexpen® forms. The purpose of the guideline is to support clinicians in selecting and safely initiating alternative basal insulins in advance of the Levemir® (insulin detemir) discontinuation. Due to the large number of people living with diabetes (Type 1, 2, 3c (pancreatic), diabetes in pregnancy and gestational diabetes) on Levemir® a planned and pro-active approach is essential.

Back to HSE National Central Repository